Vis enkel innførsel

dc.contributor.authorHalfdanarson, Oskar
dc.contributor.authorCohen, Jacqueline Mallory
dc.contributor.authorKarlstad, Øystein
dc.contributor.authorCesta, Carolyn E.
dc.contributor.authorBjørk, Marte-Helene
dc.contributor.authorHåberg, Siri Eldevik
dc.contributor.authorEinarsdottir, Kristjana
dc.contributor.authorFuru, Kari
dc.contributor.authorGissler, Mika
dc.contributor.authorHjellvik, Vidar
dc.contributor.authorKieler, Helle
dc.contributor.authorLeinonen, Maarit
dc.contributor.authorNørgaard, Mette
dc.contributor.authorEssen, Buket Öztürk
dc.contributor.authorUlrichsen, Sinna Pilgaard
dc.contributor.authorReutfors, Johan
dc.contributor.authorZoega, Helga
dc.date.accessioned2022-01-31T09:29:23Z
dc.date.available2022-01-31T09:29:23Z
dc.date.created2022-01-20T09:07:24Z
dc.date.issued2021
dc.identifier.issn1362-0347
dc.identifier.urihttps://hdl.handle.net/11250/2975859
dc.description.abstractBackground Antipsychotics are increasingly used among women of childbearing age and during pregnancy. Objective To determine whether children exposed to antipsychotics in utero are at increased risk of attention-deficit/hyperactivity disorder (ADHD) or autism spectrum disorder (ASD), accounting for maternal diagnoses of bipolar, psychotic and other psychiatric disorders. Design Population-based cohort study, including a sibling analysis. Setting Nationwide data on all pregnant women and their live-born singletons in Denmark (1997-2017), Finland (1996-2016), Iceland (2004-2017), Norway (2004-2017), and Sweden (2006-2016). Participants 4 324 086 children were eligible for inclusion to the study cohort. Intervention Antipsychotic exposure in utero, assessed by pregnancy trimester, type of antipsychotic, and varying patterns of use. Main outcome measures Non-mutually exclusive diagnoses of ADHD and ASD. We used Cox proportional hazard models to calculate hazard ratios (HRs) controlling for maternal psychiatric disorders and other potential confounding factors. Findings Among 4 324 086 singleton births, 15 466 (0.4%) were exposed to antipsychotics in utero. During a median follow-up of 10 years, we identified 72 257 children with ADHD and 38 674 children with ASD. Unadjusted HRs were raised for both outcomes but shifted substantially towards the null after adjustment; 1.10 (95%CI 1.00 to 1.27) for ADHD and 1.12 (0.97 to 1.29) for ASD. Adjusted HRs remained consistent by trimester of exposure and type of antipsychotic. Comparing in utero exposure with pre-pregnancy use yielded HRs of 0.74 (0.62 to 0.87) for ADHD and 0.88 (0.70 to 1.10) for ASD. Sibling analyses yielded HRs of 1.14 (0.79 to 1.64) for ADHD and 1.34 (0.75 to 2.39) for ASD. Discussion Our findings suggest little or no increased risk of child ADHD or ASD after in utero exposure to antipsychotics. Clinical implications Results regarding child neurodevelopment are reassuring for women who need antipsychotics during pregnancy.en_US
dc.language.isoengen_US
dc.publisherBMJ Publishing Groupen_US
dc.rightsNavngivelse-Ikkekommersiell 4.0 Internasjonal*
dc.rights.urihttp://creativecommons.org/licenses/by-nc/4.0/deed.no*
dc.titleAntipsychotic use in pregnancy and risk of attention/ deficit-hyperactivity disorder and autism spectrum disorder: a Nordic cohort studyen_US
dc.typeJournal articleen_US
dc.typePeer revieweden_US
dc.description.versionpublishedVersionen_US
dc.rights.holderCopyright Author(s) (or their employer(s)) 2021.en_US
cristin.ispublishedtrue
cristin.fulltextoriginal
cristin.qualitycode1
dc.identifier.doi10.1136/ebmental-2021-300311
dc.identifier.cristin1985643
dc.source.journalEvidence-Based Mental Healthen_US
dc.relation.projectNorges forskningsråd: 262700en_US
dc.identifier.citationEvidence-Based Mental Health, 2021.en_US


Tilhørende fil(er)

Thumbnail

Denne innførselen finnes i følgende samling(er)

Vis enkel innførsel

Navngivelse-Ikkekommersiell 4.0 Internasjonal
Med mindre annet er angitt, så er denne innførselen lisensiert som Navngivelse-Ikkekommersiell 4.0 Internasjonal